Theratechnologies inc.
TSX : TH

Theratechnologies inc.

September 30, 2007 15:57 ET

Notice of Conference Call & Media Advisory: Theratechnologies Reports 52-Week Phase 3 Results

Attention Business/Financial Editors and Analysts

MONTREAL, QUEBEC--(Marketwire - Sept. 30, 2007) - Theratechnologies (TSX:TH) advises of an upcoming conference call and webcast to discuss the 52-week results of its Phase 3 clinical trial, testing tesamorelin (TH9507), in patients with HIV-associated lipodystrophy. The call will be moderated by Dr. Andrea Gilpin, Executive Director, IR & Communications, at Theratechnologies. Mr. Yves Rosconi, President and CEO, Mr. Luc Tanguay, Senior Executive Vice President and Chief Financial Officer, Dr. Pierre Caudrelier, Chief Medical Officer and Dr. Christian Marsolais, Vice President, Clinical Research, will also be participating.

The conference call will take place tomorrow, October 1st, at 8:00 a.m. Eastern Time. Prior to the call, a press release will be issued at approximately 7:00 a.m.

October 1st, 2007 conference call and webcast

For the conference call, interested participants are asked to dial the following numbers: 416-644-3415 or 1-800-733-7571 (toll free). Please call five minutes prior to the conference in order to ensure your participation. You can access the webcast at the following links: www.investorcalendar.com and www.theratech.com.

A replay of the conference call will be available from October 1st, 2007 at 10:00 a.m. to October 8, 2007 at 11:59 p.m. at the following number: 416-640-1917, pass code 21248622# or 1-877-289-8525, code 21248622#. The webcast will be posted for 90 days at the following links: www.investorcalendar.com and www.theratech.com.

About Theratechnologies

Theratechnologies (TSX:TH) is a Canadian biopharmaceutical company that discovers innovative drug candidates in order to develop them and bring them to market. The Company targets unmet medical needs in financially attractive specialty markets. Its most advanced program is tesamorelin, which has recently completed patient recruitment for its confirmatory Phase 3 clinical trial for a serious metabolic disorder known as HIV-associated lipodystrophy. Tesamorelin could be the first compound on the market to threat HIV-associated lipodystrophy. The Company also has other projects at earlier stages of development.

Contact Information